

Neuroplastizität und Bewegung als Therapieelement bei der Schizophrenie

Psychiatrisches Kolloquium der Universität Zürich

Prof. Dr. med Peter Falkai



Klinik für Psychiatrie und Psychotherapie



**MAX-PLANCK-INSTITUT
FÜR PSYCHIATRIE**




Disclosure of financial conflict of interest

Peter Falkai received research support/honoraria for lectures or advisory activities from: Boehringer-Ingelheim, Janssen, Lundbeck, Otsuka, Recordati and Richter.

Peter Falkai holds a paid position as chairman of the Psychiatric Department of the University Munich; is full professor at the Psychiatric Department of the University Munich

Peter Falkai has received and is currently receiving grants from several national and international foundations and institutions, e.g. from the "German Science Foundation", the "German Ministry of Science" and the "German Ministry of Health"

Content



THE PATHOPHYSIOLOGY OF DEMENTIA PRAECOX (SCHIZOPHRENIA) AFTER KRAEPELIN




DEGENERATION VS. DISTURBED REGENERATION

Emil Kraepelin (1856-1925)



Emil Kraepelin

Chairman of the Psychiatric Department of the University of Munich 1903-1922



Emil Kraepelin on his round at the Psychiatric Department of the University of Munich

- Emil Kraepelin - Chairman of the Psychiatric Department of the University of Munich 1903-1922
- In 1891 Kraepelin began a research programme to quantify psychiatric disorders and eliminate any subjective biases on the part of the researcher. His aim was to place psychiatry on a more scientific foundation.
- Data were collected about every new patient that was admitted to the clinic and summarized on specially prepared index cards, his famous Zahlkarten.
- In his posthumously published Memoirs (first published in German 61 years after his death) Kraepelin described his method:



„. . . after the first thorough examination of a new patient, each of us had to throw in a note [in a "diagnosis box"] with his diagnosis written on it. After a while, the notes were taken out of the box, the diagnoses were listed, and the case was closed, the final interpretation of the disease was added to the original diagnosis. In this way, we were able to see what kind of mistakes had been made and were able to follow up the reasons for the wrong original diagnosis (p. 61).“



Alzheimer's neuroanatomical laboratory in Munich





The development of the term 'Dementia Praecox'

- Dementia praecox (a "premature dementia" or "precocious madness") refers to chronic, deteriorating psychotic disorder characterized by rapid cognitive disintegration, usually beginning in the late teens or early adulthood. It is a term first used in 1891 in this Latin form by Arnold Pick (1851–1924), a professor of psychiatry at the German branch of Charles University in Prague. It was popularized by Emil Kraepelin in 1893, 1896 and 1899 in his first detailed textbook on descriptions of a condition that would eventually be reframed into a substantially different disease concept and relabeled as schizophrenia by Eugen Bleuler
- In the 6th edition of Psychiatrie (1899), Kraepelin grouped most of the insanities into two large categories, **dementia praecox** and **manic-depressive illness**:
- (1) dementia praecox was primarily a disorder of intellectual functioning, manic depressive illness was primarily a disorder of affects or mood;
- (2) dementia praecox had a uniformly deteriorating course and a poor prognosis, manic-depressive insanity had a course of acute exacerbations followed by complete remissions with no lasting deterioration of intellectual functioning; and
- (3) there were no recoveries from dementia praecox, whereas in manic-depressive illness there were many complete recoveries.

Kraepelin's words based on Alzheimer's investigations and drawings

“ These considerations force us to draw the direct conclusion that there must be a **manifest destruction of the cortex**. In those cases that have been investigated more closely by reliable means, regular alterations have actually been demonstrated for which there is no other explanation..... .

We therefore reach the conclusion that in Dementia praecox there is **severe damage to or destruction of the nervous cortical elements**, which may be compensated for in individual cases, but which mostly results in a **peculiar, persistent impairment of the psyche.**”




Arguments against a classical neurodegenerative process

Dementia Praecox (Schizophrenia)

1	No Progression of the cognitive deficits	
2	No Loss of neuronal elements	
3	No Astrocytosis or microgliosis indicative for inflammation	
4	Synaptic Changes in schizophrenia	
5	Reversibility of structural and functional changes in schizophrenia	

No progression of cognitive deficits in schizophrenia over 5 years

FIGURE 1. Neuropsychological Summary Scale Scores for the First 5 Years in 42 Patients With First-Episode Schizophrenia and 16 Normal Comparison Subjects



No progression of cognitive deficits after 10 years compared to baseline

Table 3
Neuropsychological test results at baseline and at 10 years

	Patients (n=21)		Controls (n=8)		F values		
	Baseline	10 years	Baseline	10 years	Group	Time	Group by time
Verbal IQ ^a	97.7 ± 13.6	101.5 ± 11.3	106.1 ± 12.1	113.8 ± 10.6	6.16*	5.07*	.55
WRAT-R reading ^b	97.8 ± 15.4	99.9 ± 16.4	106.4 ± 11.3	106.5 ± 8.1	1.89	.21	.17
Log. Mem.(%)-imm. ^c	25.0 ± 1.1	25.0 ± 1.2	44.0 ± .7	47.0 ± 1.2	27.04**	.62	.38
Log. Mem.(%)-del. ^c	17 ± 1.0	16.5 ± 1.1	34.0 ± .1	38.0 ± 1.5	37.50**	.28	.65
Paired Assoc. total ^c	19.8 ± 7.7	18.1 ± 5.3	24.5 ± 3.9	21.4 ± 5.3	5.79*	1.61	.15
CVLT — total ^d	40.0 ± 12.5	36.2 ± 12.4	56.4 ± 9.7	53.1 ± 9.1	17.93**	1.67	.01
Vis. Rep.(%)-imm. ^c	58.1 ± 2.5	72.2 ± 2.2	86.6 ± 1.3	80.2 ± 3.5	7.15*	.69	4.87*
Vis. Rep.(%)-del. ^c	48.6 ± 2.6	49.2 ± 2.7	81.3 ± 1.5	87.8 ± 1.3	21.65**	.41	.28
Benton VRT—#corr. ^e	5.7 ± 2.2	5.5 ± 3.0	7.9 ± 1.4	7.8 ± 1.8	10.60***	.08	.01
Benton VRT—#err ^e	6.9 ± 4.0	7.0 ± 6.0	2.8 ± 1.9	2.8 ± 2.1	10.67***	.01	.00
WCST—#err ^f	43.0 ± 30.1	36.5 ± 26.8	14.6 ± 6.9	14.6 ± 8.4	8.94***	.32	.32
WCST—#persev. err ^f	27.9 ± 28.5	20.8 ± 15.4	7.6 ± 3.5	8.4 ± 5.2	10.13***	.33	.51
Stroop CW—#corr ^g	29.5 ± 9.5	35.8 ± 8.4	46.4 ± 7.0	53.9 ± 14.0	37.58**	6.66*	.05
Trail Making A—#sec ^h	41.2 ± 30.6	36.0 ± 19.5	21.4 ± 7.7	21.0 ± 3.7	6.64*	.35	.26
Trail Making B—#sec ^h	108.1 ± 67.3	97.7 ± 57.9	68.6 ± 22.0	55.0 ± 25.0	5.41*	2.97	.06
Fing. Tapp.-Dom ^h	41.1 ± 8.8	48.4 ± 6.8	51.4 ± 7.1	53.1 ± 8.4	9.20***	5.85*	2.19
Fing. Tapp.-NonDom ^h	39.6 ± 8.1	44.5 ± 7.9	44.3 ± 7.1	47.3 ± 6.5	1.91	8.75***	.58

^a Pro-Rated Verbal IQ (Satz and Mogel, 1962); ^b WRAT-R, Wide Range Achievement Test-Revised (Jastak and Wilkinson, 1984); ^c Wechsler Memory Scale Logical Memory and Visual Reproduction, immediate and delayed conditions, Paired Associates (Wechsler, 1945); ^d CVLT, California Verbal Learning Test (Delis et al., 1983); WCST, Wisconsin Card Sorting Test (Heaton and Crowley, 1981); ^h Trail Making Test and Finger Tapping Test, Halstead-Reitan Neuropsychological Battery (Reitan and Wolfson, 1993).

* $p < .05$.

** $p < .005$.

*** $p < .01$.

Arguments against a classical neurodegenerative process

Schizophrenia

1	No Progression of the cognitive deficits	✓
2	No Loss of neuronal elements	
3	No Astrocytosis or microgliosis indicative for inflammation	
4	Synaptic Changes in schizophrenia	
5	Reversibility of structural and functional changes in schizophrenia	

Arguments against a classical neurodegenerative process

Schizophrenia

1	No Progression of the cognitive deficits	
2	No Loss of neuronal elements	
3	No Astrocytosis or microgliosis indicative for inflammation	
4	Synaptic Changes in schizophrenia	
5	Reversibility of structural and functional changes in schizophrenia	

The pattern of structural abnormalities in schizophrenia

ENIGMA Consortium





Figure 1. Cohen's d effect sizes \pm s.e. for regional brain volume differences between Individuals with schizophrenia and healthy controls. Effect sizes for all subcortical volumes depicted were corrected for sex, age and intracranial volume (ICV). The effect size for ICV was corrected for sex and age. The number of independent data points (N_{SZ} and N_{HV}) for each region are listed in Table 1.


The posterior hippocampus in schizophrenia

Analysis of cellular subpopulations via stereology




Stereology

Analysis of Neurons




No reduction of neuronal numbers in hippocampal subfields in SZ

No sign for a degenerative process




C = controls,
S = schizophrenia,
l = left, r = right
hemisphere

Circumscribed reduction of number of oligodendrocytes in CA4



C = controls,
 S = schizophrenia,
 l = left, r = right
 hemisphere

Replication of the oligodendrocyte reduction in CA4 in an independent sample



Dentate gyrus neurons

CA4 neurons

CA4 astrocytes

CA4 oligodendrocytes

Arguments against a classical neurodegenerative process

Schizophrenia

1	No Progression of the cognitive deficits	
2	No Loss of neuronal elements	✓
3	No Astrocytosis or microgliosis indicative for inflammation	
4	Synaptic Changes in schizophrenia	
5	Reversibility of structural and functional changes in schizophrenia	

Arguments against a classical neurodegenerative process

Schizophrenia

1	No Progression of the cognitive deficits	
2	No Loss of neuronal elements	
3	No Astrocytosis or microgliosis indicative for inflammation	
4	Synaptic Changes in schizophrenia	
5	Reversibility of structural and functional changes in schizophrenia	

No Astrocytosis in Schizophrenia

Meta-analysis





Figure 5. Meta-regression in studies investigating macroglia. Forest plot showing brain region and markers as effect moderators on differences in cellular parameters. 'P-value (Subgroup vs 0 Effect)' indicates the amount of evidence for alterations in a given brain region or effects observed using a given marker. The vertical P-values indicate the added value of the moderators brain region and cell-marker in the meta-regression model. ACC, anterior cingulate cortex; SMD, standardized mean difference.

No Microgliosis in SZ? Post-mortem evidence



Pro inflammatory ↑
Anti inflammatory ↓

Imaging Microglia with PET

Meta-analysis: 4 out of 10 studies ↑, 1 ↓ and 5 no change

TABLE 2 | Positron emission tomography studies with TSPO tracer evaluating microglial activation in schizophrenia patients versus controls.

Reference	n SZ	n C	Tracer	Model; outcome measure	Clinical state Total (T) and positive symptom scale (P) score (PANSS mean ± SD unless otherwise specified)	DOI (years)	Medication % of patients on antipsychotics (AP); (mean CPZ) Benzodiazepines (BZD) excluded (duration)?	Outcome
Van Berckel et al. (56)	10	10	[11C]PK11195	2TCM; BP	Undefined Symptom scores unavailable	3.1 ± 1.7	AP 100% BZD?	SZ > C
Doorduyn et al. (57)	7	8	[11C]PK11195	2TCM; BP	Psychosis T 73.6 ± 13.3 P 19.7 ± 3.0	5 ± 6	AP 100% BZD excluded (3 × t _{1/2})	SZ > C
Banati and Hickie (66)	16	8	[11C]PK11195	2TCM; BP	Undefined Symptom scores unavailable	Range 0.3–30	Information unavailable	SZ > C
Takano et al. (58)	14	14	[11C]DAA1106	2TCM; BP	Chronic T 77.9 ± 20.1 P 19.1 ± 5.3	19 ± 12	AP 100% BZD excluded (<1 m)	SZ = C
Kenk et al. (59)	16	27	[18F]FEPPA	2TCM; V _T	Psychosis T 70.2 ± 9.7 P 19.3 ± 2.2	15 ± 9	AP 100%; (300 CPZ) BZD excluded (duration?)	SZ = C
Bloomfield et al. (55)	14	14	[11C]PBR28	2TCM-1K; DVR	Undefined T 63.7 ± 18.1 P 17.0 ± 6.1	Undefined	AP?% BZD excluded (duration?)	SZ > C
Coughlin et al. (60)	12	14	[11C]DPA713	Undefined; V _T	Undefined T unavailable P (SAPS) 3.8 ± 2.5	2.2 ± 1.4	AP?%; (474.5 CPZ) BZD excluded (6 m)	SZ = C
Van der Doef et al. (61)	19	17	[11C]PK11195	Reference tissue; BP	Undefined T 53 ± 10 P 12 ± 4	1.3 ± 1.1	AP 79% BZD excluded (4w)	SZ = C
Collste et al. (64)	16	16	[11C]PBR28	2TCM; V _T	FEP drug naïve T 77.4 ± 18.3 P 20.3 ± 4.9	0.7 ± 0.8	AP 0% BZD not excluded	SZ < C
Hafizi et al. (65)	19	20	[18F]FEPPA	2TCM; V _T	FEP unmedicated T 68.6 ± 13.0 P 19.2 ± 3.8	2.8 ± 3.3	AP 0% BZD?	SZ = C
Di Biase et al. (62)	33	27	[11C]PK11195	Reference tissue; BP	Recent-onset (n = 18) T 68.5* P (BPRS) 12.6 ± 4.6	1.5 ± 1.0	AP 78% BZD?	SZ = C
					Chronic (n = 15) T 86.5* P (BPRS) 19.5 ± 7.8	13.6 ± 8.8	AP 100% BZD?	SZ = C

SZ, schizophrenia patient group; C, control group; n, number of subjects; FEP, first-episode psychosis patients; DOI, duration of illness; 2TCM, two-tissue compartment model; BP, binding potential; V_T, total volume of distribution; DVR, distribution volume ratio; CPZ, chlorpromazine equivalent; SAPS, Scale for the Assessment of Positive Symptoms; ?, undefined.

SZ > C, increased uptake of tracer in schizophrenia patients compared to controls.

SZ = C, no difference in tracer uptake between schizophrenia patients and controls.

SZ < C, decreased uptake of tracer in schizophrenia patients compared to controls.

*Mean Brief Psychiatric Rating Scale total scores were converted to corresponding Positive and Negative Syndrome Scale total scores using the equipercentile linking method (67).

De Picker L et al. 2017: Frontiers in Psy; 8(238)

Microglia in Schizophrenia

Interpretation

Microglial but no astroglial activation: No acute inflammatory state

If the blood-brain barrier is intact: Local process in the CNS

Immune processes are involved in inflammatory processes, but also in tissue repair, homeostasis, neuroplasticity, synaptic pruning and other neurodevelopmental processes

Arguments against a classical neurodegenerative process

Schizophrenia

1	No Progression of the cognitive deficits	
2	No Loss of neuronal elements	
3	No Astrocytosis or microgliosis indicative for inflammation	✓
4	Synaptic Changes in schizophrenia	
5	Reversibility of structural and functional changes in schizophrenia	


Arguments against a classical neurodegenerative process

Schizophrenia

1	No Progression of the cognitive deficits	
2	No Loss of neuronal elements	
3	No Astrocytosis or microgliosis indicative for inflammation	
4	Synaptic Changes in schizophrenia	
5	Reversibility of structural and functional changes in schizophrenia	

Schematic representation of changes in postsynaptic elements in SZ

The schematic represents changes in postsynaptic elements in SCZ for brain regions tested with meta-analyses (unchanged or decreased) and shows which brain regions could not be tested (undetermined)



Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness

Box plots of immunoreactivities of synaptophysin, MBP and GAP-43




Fig. 4. Box plots of immunoreactivities of synaptophysin, MBP and GAP-43 in controls (con), depression (dep) and schizophrenia (sch). The schizophrenia results are also shown separated into schizophrenics who died by natural causes (sch/nat), and by suicide (sch/sui). Results represent the amount of brain protein homogenate in micrograms resulting in an optical density signal of 0.5, and are multiplied by -1 as larger amounts of protein indicate less antigen. Percentiles are indicated by boxes (25, 50, 75) and bars (10, 90) with points outside these ranges also shown. Significant reductions compared with controls; $**P = 0.01$, $*P = 0.05$ (Student–Newman–Keuls test).

Arguments against a classical neurodegenerative process

Schizophrenia

1	No Progression of the cognitive deficits	
2	No Loss of neuronal elements	
3	No Astrocytosis or microgliosis indicative for inflammation	
4	Synaptic Changes in schizophrenia	✓
5	Reversibility of structural and functional changes in schizophrenia	

Arguments against a classical neurodegenerative process

Schizophrenia

1	No Progression of the cognitive deficits	
2	No Loss of neuronal elements	
3	No Astrocytosis or microgliosis indicative for inflammation	
4	Synaptic Changes in schizophrenia	
5	Reversibility of structural and functional changes in schizophrenia	

Exercise in Rodents

Improves plasticity and learning (“cognition”)

Exercise improved the Water Maze performance, enhanced the number of Bromodeoxyuridin-positive cells and extended alternatively the long-term-potential of the Gyrus dentate in mice



Physical Activity has the capacity regulate neuroneogenesis of the hippocampus, equally **synaptic plasticity** and **learning**

Exercise I Study – Design

Group: Patients with schizophrenia

Exercise: Cycling



Frequency: 3 times/week à 30 min

Duration: 3 months

Group: Patients with schizophrenia

Exercise: table soccer



Frequency: 3 times/week à 30 min

Duration: 3 months

Group: Controls

Exercise: Cycling




Frequency: 3 times/week à 30 min

Duration: 3 months


**Effects of Exercise on
Physical capacity,
cognition and
neurobiology**

Exercise I Study

Results



- Control subjects
- ▲ Sz exercise group, treated with antidepressants
- △ Sz exercise group, not treated with antidepressants
- Sz nonexercise group, treated with antidepressants
- Sz nonexercise group, not treated with antidepressants



- Improvement of negative symptoms and short-term memory
- Normalization of hippocampal volume

Arguments against a classical neurodegenerative process

Schizophrenia


1	No Progression of the cognitive deficits	
2	No Loss of neuronal elements	
3	No Astrocytosis or microgliosis indicative for inflammation	
4	Synaptic Changes in schizophrenia	
5	Reversibility of structural and functional changes in schizophrenia	✓




AEROBIC EXERCISE AS A HUMAN MODEL FOR SZ?

Exercise I Study

Results



- Control subjects
- ▲ Sz exercise group, treated with antidepressants
- △ Sz exercise group, not treated with antidepressants
- Sz nonexercise group, treated with antidepressants
- Sz nonexercise group, not treated with antidepressants



- Improvement of negative symptoms and short-term memory
- Normalization of hippocampal volume

Exercise II Hypothesis

Combining exercise and cognitive remediation

Hypothesis:
The combination
of aerobic exercise and
cognitive remediation
(=enriched environment)
improves functioning better
than aerobic exercise alone




Figure 1. Exercise increases the production of new neurons in the dentate gyrus (DG) of the hippocampus. In two independent studies [18,19], mice were housed under (A,I) control (CON), (B,J) enriched environment only (EEO), (C,K) running (RUN), or (D,L) enriched environment and running (EER) conditions in (A–D) single or (I–L) group housing. Confocal images of bromodeoxyuridine (BrdU)-positive cells in the DG in sections derived from mice housed under (E) CON, (F) EEO (G) RUN, and (H) EER conditions. Sections were immunofluorescently double-labeled for BrdU (green) and NeuN (red) indicating neuronal phenotype (adapted from [18]). Panels (A–D) are reproduced with permission from [19]. Both studies show that adult DG neurogenesis is increased under the RUN and EER conditions but not under CON or EEO, indicating that running is the neurogenic stimulus.

Voss MW et al. 2013: Trends Cogn Sci; 10:525-44

Exercise II


Design



Timeline	Screening	Baseline/Intervention		Follow-up		
Visit-number	Visit 0	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
Time point (Day)	-14	0 ± 2	42 ± 7	84 ± 7	182 ± 14	365 ± 14
Group 1 (SZ)		CYCLING				
			COGPACK			
Group 2 (SZ)		TABLE SOCCER				
			COGPACK			
Group 3 (Controls)		CYCLING				
			COGPACK			

Exercise II

Results: Exercise has a bigger effect than cog-remediation



- **Daily functioning (GAF) ↑**
- **Social adjustment (SAS) ↑**

due to exercise and to a lesser extent to cognitive remediation.

Exercise III study in Schizophrenia (1)


Clinical symptoms

- Significant (ITT)
- Significant (PP sample)

AET
N=90

FSBT
N=90

- AET : Aerobic exercise training**
- FSBT: Flexibility Strengthening Balance Training**



- Effect of AET and FSBT on positive and negative symptomatology**
- Significance related to BL**

Exercise III study in Schizophrenia (2)



Cognitive symptoms

- Significant (ITT)
- Significant (PP sample)

AET
N=90

FSBT
N=90

- Improvement in TMT; DSST, VLMT st, It and global cognition
- Improvement of GAF and FROGS after 12 months in AET + FSBT



Why Exercise in Schizophrenia?



Improvements of positive symptom severity: $g = 0.17 - 0.54$

(Firth et al., 2015, *Psychol Med*; Dauwan et al., 2016, *Schizophr Bull*; Wei et al., 2020, *Front Psychiatry*; Fernandenz-Abascal et al., 2021, *Neurosci Biobehav Rev*; Bredin et al., 2021, *Front Cardiovasc Med*; Ziebart et al., 2022, *Front Psychiatry*; Gallardo-Gomez et al., 2023, *European Psychiatry*; Maurus et al., 2023, *Psychiatry Res*; Guo et al., 2024, *Schizophrenia*; Reißmayer et al., 2024, *Schizophr Bull*)



Improvements of negative symptom severity: $g = 0.30 - 0.65$

(Firth et al., 2015, *Psychol Med*; Dauwan et al., 2016, *Schizophr Bull*; Vogel et al. (2019), *Psychiatry Res*; Sabe et al., 2020, *Gen Hosp Psychiatry*; Wei et al., 2020, *Front Psychiatry*; Fernandenz-Abascal et al., 2021, *Neurosci Biobehav Rev*; Bredin et al., 2021, *Front Cardiovasc Med*; Ziebart et al., 2022, *Front Psychiatry*; Kim et al., 2023, *Int J Environ Res Public Health*; Gallardo-Gomez et al., 2023, *European Psychiatry*; Maurus et al., 2023, *Psychiatry Res*; Guo et al., 2024, *Schizophrenia*; Reißmayer et al., 2024, *Schizophr Bull*)



Improvements of global cognition: $g = 0.21 - 0.33$

(Firth et al., 2017, *Schizophr Bull*; Shimada et al., 2022, *Psychiatry Res*; Xu et al., 2022, *Psychiatry Res*; Maurus et al., 2023, *Psychiatry Res*)




Improvements of daily life functioning: $g = 0.32 - 0.40$

(Dauwan et al., 2016, *Schizophr Bull*; Fernandenz-Abascal et al., 2021, *Neurosci Biobehav Rev*; Kormann et al., 2023, *Schizophr Res*)


Exercise restores network functioning in Schizophrenia (1)

Functional Dysconnectivity; N=23; Link to the clinic




Exercise restores network functioning in Schizophrenia (2)

Imaging Transcriptomics



Exercise restores network functioning in Schizophrenia (3)

Imaging Transcriptomics; N=23; Link to myelin plasticity




DCI reductions



Higher expression of genes prominent in

➤ **Oligodendrocytes**




Approx. 50 % of patients show reduction of brain age after physical exercise treatment (no group effect!)

Exercise III study in Schizophrenia (3)


The hippocampus: Volume increase in CA3/CA4

- Volume increase in CA3 body, CA4 body and DG body *only in AET* not in FSBT




The posterior hippocampus in schizophrenia

The subcompartments CA1 – 4 and the subiculum




Exercise increases the volume of the hippocampal subfield C4, which is negatively correlated with the burden of risk genes of CA4/Dentate Gyrus



One of the Major Pathways targeted

“Synapse” Pathway with Synaptic Vesicle Protein 2A (SV2A)

- neuron development
- neuron differentiation
- synaptic transmission
- calcium transport
- cell adhesion
- extracellular matrix organization
- cell motility/migration
- synapse
- postsynaptic density
- ion channel activity
- cell adhesion
- pathways related to:
- glutamatergic synapsis
- focal adhesion
- calcium signaling



Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in SZ patients





Figure 1. Scatterplot showing the relationship between the optimal (p-value threshold = 0.01) oligodendrocyte precursor polygenic score (PRS^{OPC} ; x-axis, standardized) and the change from baseline (V1) in the volume of the left hippocampal subfields CA4/dentate gyrus (right panel) after 3 months of aerobic exercise (V3) (y-axis, corrected residuals). Positive values in the y-axis indicate a gain in volume after 3 months; and positive values in the x-axis, a higher genetic risk burden. Also shown are regression line and 95% confidence intervals based on the predicted means from the regression line.

Oligodendrocyte precursor Polygenic risk score
(standardized)

Oligodendrocytes and schizophrenia? Does that match?

Basis of dysconnectivity and disturbed energy supply in schizophrenia




Nature, 2012 Apr 29;485(7399):517-21. doi: 10.1038/nature11007.

Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity.


Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, Brinkmann BG, Kassmann CM, Tzvetanova ID, Möbius W, Diaz F, Meijer D, Suter U, Hamprecht B, Sereda MW, Moraes CT, Frahm J, Goebbels S, Nave KA.

Circumscribed reduction of number of oligodendrocytes in CA4



C= controls,
S= schizophrenia,
l= left, r= right
hemisphere

Replication of the oligodendrocyte reduction in CA4 in an independent sample



Dentate gyrus neurons


CA4 neurons

CA4 astrocytes


CA4 oligodendrocytes

hiPSCs-derived OPC/OLs – A model for oligodendrocyte dysfunction in SZ (1)



2D human iOL cultures



+ Doxycycline induction: overexpression lineage determining transcription factors





hiPSCs-derived OPC/OLs cluster with primary cells






hiPSCs-derived OPC/Ols – A model for oligodendrocyte dysfunction in SZ (2): Genetic analysis




hiPSC-derived iOPCs and iOLs

- cluster with human postmortem OPCs/OLs
- genes of mature iOLs are enriched in schizophrenia (SCZ) GWAS








hiPSCs-derived OPC/OLs – A model for oligodendrocyte dysfunction in SZ (3): Case Control study in 2D




- iPSC-derived OPC/OLs from patients with SCZ (cell autonomous)
- Disturbed morphology of MBP⁺ - OLs in SCZ
 - Disturbed gene expression



hiPSCs-derived OPC/Ols – A model for oligodendrocyte dysfunction in SZ (5)

Mechanistic cascade of OL dysfunction in SZ?



OL differentiation

Myelination initiation

Myelination dynamic

Impacts on neural networks

Behavioral outcomes

▶ SCZ-iOLs 2D culture


Needed (WIP):
Myelinating
human cellular
3D Model

▶ Proper Mouse Model

Impaired oligodendrocytes differentiation in mutant mice (Olig2^{+/-}/Tcf4^{+/-})

A model for oligodendrocyte dysfunction in SZ



At E18.5, a few Myrf-positive cells appear. The differentiation process can be visualized by immunohisto-chemical detection of Myrf as the central transcriptional regulator of the myelination process, whereas Mbp and Plp1 are markers of mature Ols.



Behavioral deficits in Olig2/Tcf4 double heterozygous mice

A model for oligodendrocyte dysfunction in SZ

Breeding




studying Anxiety, Learning, Long-Term-Memory among other behaviors

Note:

- 1) CNP1-KO mice display altered anxiety, Edgar et al., Transl Psychiatry, 2011
- 2) MYRF-KO: Preservation of a remote fear memory requires new myelin formation. Pan S, et al. Nat Neurosci. 2020

KO mice showed significantly decreased freezing episodes in context stage



=> Impaired remote fear memory




Shapiro-Wilk test, Levene's Test → t test (Context freezing episode, cue freezing episode), Wilcoxon/Mann-Whitney test
* $p < 0.05$

Remote fear memory test

Measure the retention of fear memory
Freezing: index of fear memory



Myelin-impaired mice exhibit deficient remote, but not recent, fear memory recall




Myelin regulatory factor (MyRF)

DISTURBED MYELIN PLASTICITY IN SZ


TRANSLATION INTO THE CLINIC AND BACK

Hypothesis: Decreased myelination and oligodendrocyte (OL) differentiation lead to impaired connectivity in schizophrenia


Controls: OLs myelinate interneurons and projections



Schizophrenia: impaired myelination and OL differentiation



OL differentiation stimulation pathways



Personal Communication
with Emily Chang, AG Molecular and
Behavioural Neurobiology
Department of Psychiatry,
Munich University Hospital

Pharmacological treatment of disturbed myelin plasticity



Clemastine

- Histamine H1 antagonist
- P2X7 receptor positive allosteric modulator. *Wolfgang Nörenberg et al., J Biol Chem., 2011 (10.1074/jbc.M110.198879)*
- Muscarinic M1 receptors (M1Rs) antagonist
- M1Rs are expressed by oligodendroglial cells and may modulate OPC proliferation and differentiation. *Federica De Angelis et al., Developmental Neurobiology, 2011 (doi.org/10.1002/dneu.20976)*

The OligoTreat Study

Combining Clemastine with Aerobic Exercise


The OligoTreat Study:
Aerobic exercise combined with clemastine treatment and cognition in schizophrenia patients



MARS – Effects of Quetiapine Augmentation on Cognitive Flexibility in Depression



3) WCST: Cognitive Flexibility prior to Discharge




- While general performance in the WCST (number of identified sorting rules) was similar, QET (+) showed substantially higher cognitive flexibility indicated by a lower error rate, and specifically, by a lower rate of perseveration errors in this test. This effect remains significant after correcting for residual depression symptoms at the time of the test. The number of QET (+) treatment weeks - but not the average daily dosage - correlates significantly with low perseveration errors: $r = -.385$ ($p < .001$).




DEVELOPING A BIOMARKER FOR SUBTYPING THE
LONGITUDINAL COURSE OF SCHIZOPHRENIA


NfL as a marker for short- and long-term outcome in SZ





Normal and extended NfL biomarker model



NfL in SZ (vs. controls), aging, subtypes and longitudinal course




Focus on ultrasound to stimulate connectome hubs individually



Pines AR et al. 2025: JAMA Psychiatry. Published online February 12, 2025

Figure 2. Functional Connections of Lesions That Cause Different Symptoms of Psychosis and Correlation Values



Functional connections of lesions that cause different symptoms of psychosis share a common functional connection to the posterior subiculum of the hippocampus, and are more correlated with each other. A, Each grouping of psychotic symptoms had peak sensitivity (overlap >75%) and specificity (P for family-wise error $< 5 \times 10^{-4}$) in the posterior subiculum of the hippocampus (outlined in white). No individual voxels from the negative symptoms subgroup

remained significant after correcting for multiple comparisons. B, Spatial correlation values between the psychosis circuit and each symptom group. When correlating between the psychosis circuit and each psychotic symptom group, lesions from the psychotic group being examined were excluded from the psychosis circuit they were being correlated with.

Summary



The pathophysiology of schizophrenia: disturbed plasticity instead of degeneration

Aerobic exercise: Understanding an cure

From the human to the animal model: e.g. tg TCF4/Olig II

From mechanism to clinic: e.g. Clemastine, Quetiapine, aerobic exercise

NFL plus: A tentative biomarker for disturbed myelin plasticity to subtype the longitudinal course of SZ
=> "instable plastic vs. stable plastic subtype"

People contributing to the work

**Andrea
Schmitt**



Post-mortem studies

**Moritz
Rossner**



Animal models

**Sergi
Papiol**



Genetics

**Isabel
Maurus**



Sport Psych.

**Lukas
Röll**



Sport Psych.

**Florian
Raabe**



iPSCs



**Top row, left to right: Lotmar (1), Rosenthal (3), Allers (4),
Alzheimer (6), Achucarro (7), Lewy (8)**

Seated: Grombach (1), Cerletti (2), Bonfiglio (4), Perusini (5)

**Thank you
for your attention**